Botulinum toxin in the treatment of orofacial tardive dyskinesia: A single blind study

Christina W. Slotema; Peter N. van Harten; Richard Bruggeman; Hans W. Hoek

doi:10.1016/j.pnpbp.2007.10.004

Botulinum toxin in the treatment of orofacial tardive dyskinesia: A single blind study

Christina W. Slotema, Peter N. van Harten, Richard Bruggeman, Hans W. Hoek^*

^*Bijbehorende auteur voor dit werk

Faculteit Medische Wetenschappen/UMCG

Onderzoeksoutput › Academic › peer review

25 Citaten (Scopus)

Samenvatting

Objective: Orofacial tardive dyskinesia (OTD) is difficult to treat and Botulinium Toxin A (BTA) may be an option.

Methods: In a single blind (raters were blind) study (N= 12, duration 33 weeks) OTD was treated with Botulinum Toxin A in three consecutive sessions with increasing dosages. The severity was measured with the Abnormal Involuntary Movement Scale (AIMS).

Results: Overall there was a non-significant reduction in the severity of OTD (p=0.15). However, in the patients with no change in their anti psychotic medication (N= 8) the reduction was significant (p=0.035). After the study, 50% of the patients preferred to continue the Botulinum Toxin A treatment.

Originele taal-2	English
Pagina's (van-tot)	507-509
Aantal pagina's	3
Tijdschrift	Progress in Neuro-Psychopharmacology & Biological Psychiatry
Volume	32
Nummer van het tijdschrift	2
DOI's	https://doi.org/10.1016/j.pnpbp.2007.10.004
Status	Published - 15-feb-2008
Evenement	13th Biennial Winter Workshop on Schizophrenia Research - Davos, Switzerland Duur: 4-feb-2006 → 10-feb-2006

Toegang tot document

10.1016/j.pnpbp.2007.10.004

Citeer dit

@article{2cae4b15f5bb486a8161a0024402bf36,

title = "Botulinum toxin in the treatment of orofacial tardive dyskinesia: A single blind study",

abstract = "Objective: Orofacial tardive dyskinesia (OTD) is difficult to treat and Botulinium Toxin A (BTA) may be an option.Methods: In a single blind (raters were blind) study (N= 12, duration 33 weeks) OTD was treated with Botulinum Toxin A in three consecutive sessions with increasing dosages. The severity was measured with the Abnormal Involuntary Movement Scale (AIMS).Results: Overall there was a non-significant reduction in the severity of OTD (p=0.15). However, in the patients with no change in their anti psychotic medication (N= 8) the reduction was significant (p=0.035). After the study, 50% of the patients preferred to continue the Botulinum Toxin A treatment.Conclusion: BTA was well tolerated and showed a non-significant improvement for OTD. A larger double blind study is warranted. (c) 2007 Elsevier Inc. All rights reserved.",

keywords = "antipsychotic agents, Botulinum toxin, orofacial tardive dyskinesia, CURACAO EXTRAPYRAMIDAL SYNDROMES, DYSTONIA",

author = "Slotema, {Christina W.} and {van Harten}, {Peter N.} and Richard Bruggeman and Hoek, {Hans W.}",

year = "2008",

month = feb,

day = "15",

doi = "10.1016/j.pnpbp.2007.10.004",

language = "English",

volume = "32",

pages = "507--509",

journal = "Progress in Neuro-Psychopharmacology & Biological Psychiatry",

issn = "1878-4216",

publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

number = "2",

note = "13th Biennial Winter Workshop on Schizophrenia Research ; Conference date: 04-02-2006 Through 10-02-2006",

}

TY - JOUR

T1 - Botulinum toxin in the treatment of orofacial tardive dyskinesia

T2 - 13th Biennial Winter Workshop on Schizophrenia Research

AU - Slotema, Christina W.

AU - van Harten, Peter N.

AU - Bruggeman, Richard

AU - Hoek, Hans W.

PY - 2008/2/15

Y1 - 2008/2/15

N2 - Objective: Orofacial tardive dyskinesia (OTD) is difficult to treat and Botulinium Toxin A (BTA) may be an option.Methods: In a single blind (raters were blind) study (N= 12, duration 33 weeks) OTD was treated with Botulinum Toxin A in three consecutive sessions with increasing dosages. The severity was measured with the Abnormal Involuntary Movement Scale (AIMS).Results: Overall there was a non-significant reduction in the severity of OTD (p=0.15). However, in the patients with no change in their anti psychotic medication (N= 8) the reduction was significant (p=0.035). After the study, 50% of the patients preferred to continue the Botulinum Toxin A treatment.Conclusion: BTA was well tolerated and showed a non-significant improvement for OTD. A larger double blind study is warranted. (c) 2007 Elsevier Inc. All rights reserved.

AB - Objective: Orofacial tardive dyskinesia (OTD) is difficult to treat and Botulinium Toxin A (BTA) may be an option.Methods: In a single blind (raters were blind) study (N= 12, duration 33 weeks) OTD was treated with Botulinum Toxin A in three consecutive sessions with increasing dosages. The severity was measured with the Abnormal Involuntary Movement Scale (AIMS).Results: Overall there was a non-significant reduction in the severity of OTD (p=0.15). However, in the patients with no change in their anti psychotic medication (N= 8) the reduction was significant (p=0.035). After the study, 50% of the patients preferred to continue the Botulinum Toxin A treatment.Conclusion: BTA was well tolerated and showed a non-significant improvement for OTD. A larger double blind study is warranted. (c) 2007 Elsevier Inc. All rights reserved.

KW - antipsychotic agents

KW - Botulinum toxin

KW - orofacial tardive dyskinesia

KW - CURACAO EXTRAPYRAMIDAL SYNDROMES

KW - DYSTONIA

U2 - 10.1016/j.pnpbp.2007.10.004

DO - 10.1016/j.pnpbp.2007.10.004

M3 - Article

VL - 32

SP - 507

EP - 509

JO - Progress in Neuro-Psychopharmacology & Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology & Biological Psychiatry

SN - 1878-4216

IS - 2

Y2 - 4 February 2006 through 10 February 2006

ER -